The lancet oncology

• Latest
• Best
• Search…

• The lancet oncology · Feb 2012

  NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV follicular lymphoma in previously untreated patients.

  no abstract available

  read on… or not…

• The lancet oncology · Feb 2012

  NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.

  no abstract available

  read on… or not…

• The lancet oncology · Feb 2012

  Comment

  Nasopharyngeal cancer: a promising future.

  no abstract available

  keep reading… or just mark as read…

• The lancet oncology · Feb 2012

  Persian Gulf states outline regional approach to tackle cancer.

  no abstract available

  keep reading… or not…

• The lancet oncology · Feb 2012

  Randomized Controlled Trial

  Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

  Targeting of VEGF is a potential therapeutic option in patients with malignant ovarian ascites. We present the final results of a multicentre study of the efficacy and safety of aflibercept, a potent inhibitor of both VEGF and placental growth factor, in the treatment of malignant ascites. ⋯ Sanofi Oncology.

  expand abstract… or just mark as read…